Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00336492 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
A Phase 3 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT00336492 is a Phase 3 study that has completed, run by Centocor. The registered enrollment target is 60 participants.
The verdict
NCT00336492, a Phase 3 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in children with moderately to severely active ulcerative colitis.
Interventions
- BIOLOGICAL infliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00336492
The ClinicalTrials.gov registry entry for NCT00336492 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which infliximab is the first listed.
NCT00336492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00336492 about?
NCT00336492 is a clinical study titled "A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis". The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in children with moderately to severely active ulcerative colitis.
What is the current status of trial NCT00336492?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2006-09. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00336492?
The interventions under investigation include: infliximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00336492?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.